Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 584

1.

Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.

Yu R, Song D, DuBois DC, Almon RR, Jusko WJ.

AAPS J. 2019 Jul 24;21(5):93. doi: 10.1208/s12248-019-0362-6.

PMID:
31342216
2.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat.

Ayyar VS, Song D, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):318-326. doi: 10.1124/jpet.119.257519. Epub 2019 Jun 13.

PMID:
31197020
3.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part II: Sex Differences in Methylprednisolone Pharmacokinetics and Corticosterone Suppression.

Ayyar VS, DuBois DC, Nakamura T, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):327-336. doi: 10.1124/jpet.119.257527. Epub 2019 Jun 13. Erratum in: J Pharmacol Exp Ther. 2019 Sep;370(3):436.

PMID:
31197019
4.

Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part III: Estrous Cycle and Estrogen Receptor-Dependent Antagonism of Glucocorticoid-Induced Leucine Zipper (GILZ) Enhancement by Corticosteroids.

Ayyar VS, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2019 Aug;370(2):337-349. doi: 10.1124/jpet.119.257543. Epub 2019 Jun 13.

PMID:
31197018
5.

Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women.

Barcellos T, Natavio M, Stanczyk FZ, Luo D, Jusko WJ, Bender NM.

Contraception. 2019 Oct;100(4):283-287. doi: 10.1016/j.contraception.2019.06.002. Epub 2019 Jun 10.

PMID:
31194965
6.

ATLAS mPBPK: a MATLAb-based tool for modeling and Simulation of minimal Physiologically Based PharmacoKinetic models.

Mavroudis PD, Ayyar VS, Jusko WJ.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun 2. doi: 10.1002/psp4.12441. [Epub ahead of print]

7.

Pathway-Based Analysis of the Liver Response to Intravenous Methylprednisolone Administration in Rats: Acute Versus Chronic Dosing.

Acevedo A, Berthel A, DuBois D, Almon RR, Jusko WJ, Androulakis IP.

Gene Regul Syst Bio. 2019 Apr 15;13:1177625019840282. doi: 10.1177/1177625019840282. eCollection 2019.

8.

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ.

J Clin Pharmacol. 2019 Jul;59(7):979-988. doi: 10.1002/jcph.1388. Epub 2019 Feb 11.

PMID:
30742306
9.

Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index.

Natavio M, Stanczyk FZ, Molins EAG, Nelson A, Jusko WJ.

Contraception. 2019 May;99(5):306-311. doi: 10.1016/j.contraception.2019.01.003. Epub 2019 Jan 28.

PMID:
30703352
10.

Indirect pharmacodynamic models for responses with circadian removal.

Ayyar VS, Krzyzanski W, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2019 Feb;46(1):89-101. doi: 10.1007/s10928-019-09620-z. Epub 2019 Jan 29.

PMID:
30694437
11.

Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals.

Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF.

J Control Release. 2019 Mar 10;297:39-47. doi: 10.1016/j.jconrel.2019.01.030. Epub 2019 Jan 23.

PMID:
30684512
12.

Altered pharmacokinetics of combined oral contraceptives in obesity - multistudy assessment.

Luo D, Westhoff CL, Edelman AB, Natavio M, Stanczyk FZ, Jusko WJ.

Contraception. 2019 Apr;99(4):256-263. doi: 10.1016/j.contraception.2018.12.009. Epub 2019 Jan 23.

PMID:
30684471
13.

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR.

Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13.

14.

Modeling Sex Differences in Anti-inflammatory Effects of Dexamethasone in Arthritic Rats.

Song D, DuBois DC, Almon RR, Jusko WJ.

Pharm Res. 2018 Sep 6;35(11):203. doi: 10.1007/s11095-018-2483-5.

PMID:
30191329
15.

Modeling Corticosteroid Pharmacogenomics and Proteomics in Rat Liver.

Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2018 Oct;367(1):168-183. doi: 10.1124/jpet.118.251959. Epub 2018 Aug 7.

16.

Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.

Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):549-561. doi: 10.1002/psp4.12320. Epub 2018 Aug 9.

17.

Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

Zhu X, Trueman S, Straubinger RM, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):733-746. doi: 10.1007/s10928-018-9603-z. Epub 2018 Aug 1.

18.

Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model.

Li X, Jusko WJ, Cao Y.

J Pharmacol Exp Ther. 2018 Oct;367(1):1-8. doi: 10.1124/jpet.118.250134. Epub 2018 Jul 12.

19.

Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.

Molins EAG, Jusko WJ.

AAPS J. 2018 Jun 27;20(5):80. doi: 10.1208/s12248-018-0235-4.

PMID:
29951754
20.

Modeling circadian variability of core-clock and clock-controlled genes in four tissues of the rat.

Mavroudis PD, DuBois DC, Almon RR, Jusko WJ.

PLoS One. 2018 Jun 12;13(6):e0197534. doi: 10.1371/journal.pone.0197534. eCollection 2018.

21.

Daily variation of gene expression in diverse rat tissues.

Mavroudis PD, DuBois DC, Almon RR, Jusko WJ.

PLoS One. 2018 May 10;13(5):e0197258. doi: 10.1371/journal.pone.0197258. eCollection 2018.

22.

Receptor/gene/protein-mediated signaling connects methylprednisolone exposure to metabolic and immune-related pharmacodynamic actions in liver.

Ayyar VS, Sukumaran S, DuBois DC, Almon RR, Qu J, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):557-575. doi: 10.1007/s10928-018-9585-x. Epub 2018 Apr 27.

PMID:
29704219
23.

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.

Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.

Front Pharmacol. 2018 Feb 19;9:84. doi: 10.3389/fphar.2018.00084. eCollection 2018.

24.

Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice.

Chen X, Jiang X, Doddareddy R, Geist B, McIntosh T, Jusko WJ, Zhou H, Wang W.

J Pharmacol Exp Ther. 2018 Apr;365(1):140-155. doi: 10.1124/jpet.117.244855. Epub 2018 Feb 2.

PMID:
29420255
25.

Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy.

McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS.

PM R. 2018 Mar;10(3):235-243. doi: 10.1016/j.pmrj.2017.08.441. Epub 2017 Sep 1.

26.

Mechanistic Multi-Tissue Modeling of Glucocorticoid-Induced Leucine Zipper Regulation: Integrating Circadian Gene Expression with Receptor-Mediated Corticosteroid Pharmacodynamics.

Ayyar VS, DuBois DC, Almon RR, Jusko WJ.

J Pharmacol Exp Ther. 2017 Oct;363(1):45-57. doi: 10.1124/jpet.117.242990. Epub 2017 Jul 20.

27.

Effects of High-Fat Feeding on Skeletal Muscle Gene Expression in Diabetic Goto-Kakizaki Rats.

Nie J, DuBois DC, Xue B, Jusko WJ, Almon RR.

Gene Regul Syst Bio. 2017 May 29;11:1177625017710009. doi: 10.1177/1177625017710009. eCollection 2017.

28.

Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen.

Li X, DuBois DC, Song D, Almon RR, Jusko WJ, Chen X.

Drug Metab Dispos. 2017 Jul;45(7):834-845. doi: 10.1124/dmd.117.075614. Epub 2017 Apr 17.

29.

Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor-α in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.

Chen X, DuBois DC, Almon RR, Jusko WJ.

Drug Metab Dispos. 2017 Jul;45(7):790-797. doi: 10.1124/dmd.116.074807. Epub 2017 Apr 14.

30.

Characterization and Interspecies Scaling of rhTNF-α Pharmacokinetics with Minimal Physiologically Based Pharmacokinetic Models.

Chen X, DuBois DC, Almon RR, Jusko WJ.

Drug Metab Dispos. 2017 Jul;45(7):798-806. doi: 10.1124/dmd.116.074799. Epub 2017 Apr 14.

31.

Functional proteomic analysis of corticosteroid pharmacodynamics in rat liver: Relationship to hepatic stress, signaling, energy regulation, and drug metabolism.

Ayyar VS, Almon RR, DuBois DC, Sukumaran S, Qu J, Jusko WJ.

J Proteomics. 2017 May 8;160:84-105. doi: 10.1016/j.jprot.2017.03.007. Epub 2017 Mar 14.

32.

Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels.

Kamisoglu K, Acevedo A, Almon RR, Coyle S, Corbett S, Dubois DC, Nguyen TT, Jusko WJ, Androulakis IP.

Front Pharmacol. 2017 Feb 27;8:91. doi: 10.3389/fphar.2017.00091. eCollection 2017.

33.

Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.

Li X, DuBois DC, Almon RR, Jusko WJ.

Drug Metab Dispos. 2017 May;45(5):484-491. doi: 10.1124/dmd.116.074526. Epub 2017 Feb 28.

34.

Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Li X, DuBois DC, Almon RR, Jusko WJ.

Drug Metab Dispos. 2017 May;45(5):476-483. doi: 10.1124/dmd.116.074500. Epub 2017 Feb 28.

35.

Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest.

Vali P, Chandrasekharan P, Rawat M, Gugino S, Koenigsknecht C, Helman J, Jusko WJ, Mathew B, Berkelhamer S, Nair J, Wyckoff MH, Lakshminrusimha S.

J Am Heart Assoc. 2017 Feb 18;6(2). pii: e004402. doi: 10.1161/JAHA.116.004402.

36.

Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.

Koch G, Jusko WJ, Schropp J.

J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):27-42. doi: 10.1007/s10928-016-9502-0. Epub 2017 Jan 10.

37.

Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.

Koch G, Jusko WJ, Schropp J.

J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):17-26. doi: 10.1007/s10928-016-9501-1. Epub 2017 Jan 10.

38.

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.

Miao X, Koch G, Ait-Oudhia S, Straubinger RM, Jusko WJ.

Front Pharmacol. 2016 Nov 15;7:421. eCollection 2016.

39.

Assessment of non-linear combination effect terms for drug-drug interactions.

Koch G, Schropp J, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2016 Oct;43(5):461-79. doi: 10.1007/s10928-016-9490-0. Epub 2016 Sep 16. Review.

40.

Clarification of contraceptive drug pharmacokinetics in obesity.

Jusko WJ.

Contraception. 2017 Jan;95(1):10-16. doi: 10.1016/j.contraception.2016.08.003. Epub 2016 Aug 16. Review.

41.

Perspectives on variability in pharmacokinetics of an oral contraceptive product.

Jusko WJ.

Contraception. 2017 Jan;95(1):5-9. doi: 10.1016/j.contraception.2016.07.019. Epub 2016 Jul 27. Review.

42.

Mathematical modeling of the circadian dynamics of the neuroendocrine-immune network in experimentally induced arthritis.

Rao R, DuBois D, Almon R, Jusko WJ, Androulakis IP.

Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E310-24. doi: 10.1152/ajpendo.00006.2016. Epub 2016 May 24.

43.

Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis.

Chen X, Jiang X, Jusko WJ, Zhou H, Wang W.

J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):291-304. doi: 10.1007/s10928-016-9472-2. Epub 2016 Apr 27.

44.

Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.

Miao X, Koch G, Straubinger RM, Jusko WJ.

Cancer Chemother Pharmacol. 2016 Jan;77(1):181-93. doi: 10.1007/s00280-015-2907-4. Epub 2015 Nov 25.

45.

Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.

Lon HK, DuBois DC, Earp JC, Almon RR, Jusko WJ.

Pharmacol Res Perspect. 2015 Oct;3(5):e00169. doi: 10.1002/prp2.169. Epub 2015 Aug 3.

46.

Perspectives on the history and scientific contributions of Gerhard Levy.

Fung HL, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):429-46. doi: 10.1007/s10928-015-9442-0. Epub 2015 Sep 24. No abstract available.

PMID:
26403702
47.

Preface to the special issue to honor Gerhard Levy and 50 years of PK/PD.

Jusko WJ, Fung HL.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):427. doi: 10.1007/s10928-015-9443-z. No abstract available.

PMID:
26403701
48.

Effects of High Fat Feeding on Adipose Tissue Gene Expression in Diabetic Goto-Kakizaki Rats.

Xue B, Nie J, Wang X, DuBois DC, Jusko WJ, Almon RR.

Gene Regul Syst Bio. 2015 Aug 10;9:15-26. doi: 10.4137/GRSB.S25172. eCollection 2015.

49.

Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.

Zhu X, Straubinger RM, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):477-96. doi: 10.1007/s10928-015-9429-x. Epub 2015 Aug 8.

50.

Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.

Yoo H, Iirola T, Vilo S, Manner T, Aantaa R, Lahtinen M, Scheinin M, Olkkola KT, Jusko WJ.

Eur J Clin Pharmacol. 2015 Oct;71(10):1197-207. doi: 10.1007/s00228-015-1913-0. Epub 2015 Aug 2.

PMID:
26233335

Supplemental Content

Loading ...
Support Center